Washington, DC – The Association of Clinical Research Professionals (ACRP) today announces formation of a multi-stakeholder task force charged with defining the core competencies required of entry-level clinical research associates (CRAs).
The task force will identify the competencies required of entry-level CRAs (also known as monitors), develop measures of competence, and advocate for standardization of identified CRA competencies across the clinical research enterprise.
This announcement follows publication this week by ACRP of a position paper examining the current CRA workforce and calling for elimination of the commonly accepted and practiced two-year experience requirement for entry-level CRAs in favor of competence-based employment practices (see: A New Approach to Developing the CRA Workforce).
"The arbitrary 2-years' experience requirement is contributing to a shortage of CRAs in the clinical research profession and is leading to inefficiencies at contract research organization and clinical trial sponsors while doing nothing to ensure quality in clinical research," says Terri Hinkley, RN, BScN, MBA, CCRC, ACRP Interim Executive Director. "By leading this initiative ACRP plans to drive a shift in the profession that will both address the existing workforce pipeline issues and improve the quality conduct of clinical research."
As noted in ACRP's position paper, there are at least 10,000 CRA open positions in the United States alone, and there is no evidence to suggest that number will decline any time soon. A recent Brookings study, lamenting an overall employee shortage throughout the life sciences industry, singled out the CRA as one of the positions most in need of recruitment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.